No abstract

The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of ovarian neoplasms specifically related to the management of peritoneal surface malignancy. These guidelines are developed with input from leading experts, including surgical oncologists, medical oncologists, gynecologic oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness in the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence. Cancer 2020;126:2553-2560. Communication 2554Cancer June 1, 2020 seeding and upstaging of a potentially early-stage cancer. The most common histologic diagnosis is high-grade serous cancer (66% of EOCs), with mucinous cancer, endometrioid cancer, and carcinosarcoma each accounting for about 10%. Clear cell carcinoma and low-grade serous carcinomas are less frequent, accounting for less than 5% of the remaining cancers, and have a strong association with endometriosis and borderline tumors, respectively. Pathological diagnosis should be verified by an experienced gynecologic pathologist and confirmed by immunohistochemical markers that can help to distinguish ovarian cancer from cancers metastatic to the ovary (eg, CK7, CK20, CA125, CEA, WT1, PAX8, p53, estrogen receptor/progesterone receptor). Accurate identification of low-grade serous carcinomas is See companion articles on pages

No abstract

No abstract

The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of neuroendocrine tumors specifically related to the management of peritoneal surface malignancy. These guidelines are developed with input from leading experts, including surgical oncologists, medical oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness in the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence. Cancer 2020;126:2561-2565.